1. Trends & External Forces

2025 Brand Drug Challenges: A GoodRx Perspective

Written by Posted on Less than 0 min read

Today’s guest post is from Dorothy Gemmell, Chief Commercial Officer and President, Manufacturer Solutions, at GoodRx.

Dorothy highlights five trends to watch in 2025. She then describes how GoodRx’s Cash Point-of-Sale Solution can help brands improve gross-to-net (GTN) while also making medications more affordable for patients.

Click here to download the latest GoodRx data on copay, cash, and patient services programs.

Read on for Dorothy’s insights.


Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Trends & External Forces

Medicare Part D in 2024: The Seven Largest Companies’ Preferred Pharmacy Networks and the Coming Collapse of the PDP Market

Open enrollment is under way for the 2024 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as a component of Part D benefit design. For 2024: 94% of stand-alone Medicare Part D prescription drug plans (PDP) […]
2 min read
0
  1. Trends & External Forces

Anti-Obesity Drugs and The Coming Battle Over Utilization Management (video)

My recent Drug Channels Outlook 2024 webinar covered 12 key trends that will shape the commercial environment this year. The video excerpt below highlights my commentary on trend #2: the rapid growth of anti-obesity GLP-1 agonist drugs. As I explain, this growth will challenge payer and channel economics, while boosting profits for patient reimbursement hub […]
2 min read
0
  1. Trends & External Forces

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Click here to see the original post from December 2023. Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a […]
2 min read
0
  1. Trends & External Forces

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers’ preparation. To learn more, register […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, June 2024: Cordavis Humira Update, OptumRx’s New Biosim Biz, Generic Drugs’ Wild Ride, IRA Predictions, and Dr. G on Med School

Happy 248th birthday, America! Before you launch your July 4 festivities, Drug Channels offers some fireworks of its own: CVS Health’s Cordavis is winning the Humira biosimilar battle Meet NUVAILA, OptumRx’s new biosimilar procurement business The acquisition cost revolution hits a speedbump following NADAC volatility Five predictions about the IRA’s impact on the drug channel […]
2 min read
0
  1. Data & Insights

Informa Connect’s Patient Support Services Congress

Informa Connect’s Patient Support Services Congress November 7-9, 2023 The Inn at Penn, Philadelphia, PA https://informaconnect.com/patient-support-services/ Exclusive Offer – Be sure to use your exclusive promo code 23DC10 to save 10% off* of your registration. The Patient Support Services Congress is a dialogue-driven meeting that arms the industry with innovative trends and next-generation approaches to […]
3 min read
0
  1. Trends & External Forces

The Drug Discount Ecosystem Needs Clarity in 2024 and Beyond

Today’s guest post comes from Gavin Magaha, Senior Director of Value Delivery at Kalderos. Gavin discusses the problems manufacturers face in accessing and standardizing drug discount data. These data are necessary to avoid duplicate discounts and comply with regulatory requirements. To learn more about how the Inflation Reduction Act adds to challenges of drug discount […]
2 min read
0
  1. Data & Insights

Unlocking AI’s Promise in Patient Support Programs

Today’s guest post comes from Chris Apolito, Chief Strategy Officer, and Karina Castagna, Senior Vice President, Commercial Strategy at Mercalis. Chris and Karina describe four ways that artificial intelligence (AI) can improve patient access, affordability, and adherence. To learn more, join Mercalis for a complimentary webinar on March 13, 2025: Modernizing Patient Support: Harnessing Advanced […]
2 min read
0
  1. Department: HBC

Hospitals Are Relying More on PBMs to Manage Manufacturers’ 340B Contract Pharmacy Restrictions: DCI’s 2024 Market Analysis

The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program.  Five multi-billion-dollar, for-profit, publicly traded pharmacy […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2024: Smaller Pharmacies Abandon Preferred Pharmacy Networks

In a previous article, I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). Today, I update DCI’s exclusive analysis of how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As […]
2 min read
0
  1. Media & Marketing

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on our new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Since I published the article below in July 2023, there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of […]
3 min read
0
  1. Corporate Strategy

Meet the Four Executives Headlining the Drug Channels Leadership Forum

Good news, everyone! We have secured four outstanding fireside chat participants for our inaugural Drug Channels Leadership Forum, which will be held next March in Miami. I’ll be leading one-on-one conversations with each of these executives: Steven H. Collis, Chairman, President, and CEO, Cencora, Inc. Patrick Conway, MD, MSc, CEO, Optum Rx Frank Cunningham, Group […]
2 min read
0
  1. Shopper & Customer

Best Practices for Successfully Transitioning a Patient Services Hub

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health Josh discusses challenges manufacturers may face when outsourcing patient support programs. He outlines a process that smoothly transitions hubs and minimizes disruptions for patients and healthcare providers. To learn more, download the 3-step guide to […]
2 min read
0
  1. Trends & External Forces

EXCLUSIVE: The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021 (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. My topic #9 for 2024: The Battle Over 340B Gets Even Messier. Click here to see the original post from September 2023. Drug Channels has just obtained new details on the size of the 340B Drug […]
3 min read
0
  1. Channel: Drug

Drug Channels News Roundup, April 2024: CVS’s Humira Strategy, White Bagging “Savings,” IRA vs. Part D Plans, Walgreens Specialty Update, Pharmacies vs. GoodRx, and Oncology Fun

April is over, so it’s time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients? My $0.02 on how Medicare Part D plans will react to the Inflation Reduction Act Walgreens’ unexpected specialty pharmacy strength […]
2 min read
0
  1. Data & Insights

From Data Gaps to Revenue Gains: Harnessing the Power of Comprehensive Data to Drive GTN

Today’s guest post comes from Thomas Luby, Sr. Vice President, Business Development at PHIL. Thomas discusses the challenges brands face as they manage gross-to-net (GTN) performance while simultaneously enhancing patient access and adherence. He lists the key performance indicators that can help brands improve GTN. To learn more, watch PHIL’s free on-demand webinar: Four Patient Access […]
2 min read
0
  1. Trends & External Forces

The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents

Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. We have identified nearly 1,800 dispensing sites with specialty pharmacy accreditation—about 40% of which are owned by hospitals, physician practices, and other healthcare providers. Alas, specialty pharmacies owned by the three largest […]
2 min read
0
  1. Media & Marketing

A Clear Path to Education Affordability Requires Meeting Patients Where They Are

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. Kristina shares the story of a patient who cut pills in half to extend her prescriptions. Unfortunately, this patient didn’t know about manufacturer affordability programs. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, […]
2 min read
0
  1. Sponsored

Repairing the Patient Journey: How Pharma Can Fix the Obvious–and Not So Obvious–Breaking Points of Nonadherence

Today’s guest post comes from Maria Kirsch, President, Patient Services, Krista Pinto, President, Deployment Solutions, and Mike Scott, Senior Vice President, Specialty Consulting at EVERSANA. Maria, Krista, and Mike discuss the key reasons why patients abandon drug therapy. They then describe EVERSANA’s approach for helping manufacturers and healthcare providers improve adherence and health outcomes. Learn […]
2 min read
0
  1. Trends & External Forces

The 340B Drug Pricing Program: Trends, Controversies, and Outlook (NEW Live Video Webinar)

Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m. ET This […]
3 min read
0
Next